PBP1502
Adalimumab Biosimilar
Overview
- PBP1502
Adalimumab Biosimilar (Humira® Biosimilar) - Therapeutic Area: Immunology
- Indication: Arthritis
- Patent protected technology
- Status: Phase 1 clinical trial ongoing
PBP1502
Adalimumab Biosimilar
Rheumatoid Arthritis, Psoriasis, etc.
Clinical Development Program
An Overview
| Protocol number / Study type |
Title of the study | Status |
|---|---|---|
| SOLOMON-1 | A Phase 1, Double-blind, Randomized, Three-arm,Parallel Group Study to Compare the Pharmacokinetics and Safety of a Single Subcutaneous Dose of PBP1502, EU-Humira®, and US-Humira® in Healthy Male and Female Subjects |
Ongoing |
SOLOMON-1
| Protocol number / Study type |
SOLOMON-1 |
|---|---|
| Title of the study | A Phase 1, Double-blind, Randomized, Three-arm,Parallel Group Study to Compare the Pharmacokinetics and Safety of a Single Subcutaneous Dose of PBP1502, EU-Humira®, and US-Humira® in Healthy Male and Female Subjects |
| Status | Ongoing |
